ECE2020 Audio ePoster Presentations Pituitary and Neuroendocrinology (217 abstracts)
Prevalence of non-alcoholic fatty liver disease in patients with Cushing disease (CD)
Pablo Remon 1 , Eva Venegas-Moreno 1 , Alejandro Deniz-Garcia 1 , Raquel Millan 2 , Elena Dios-Fuentes 1 , Natalia Martin 2 , Maria C Rico 2 , Ainara Madrazo 3 , Manuel Romero-Gómez 4 & Alfonso Soto-Moreno 1
1Virgen del Rocio Hospital, UGC Endocrinology and Nutrition, Sevilla, Spain; 2FISEVI, Sevilla, Spain; 3FISEVI, UGC Endocrinology and Nutrition, Sevilla, Spain; 4Virgen del Rocio Hospital, UGC Digestive and Gastroenterology, Sevilla, Spain
Introduction: The prevalence and comorbidities of NAFLD in CD are unknown. There is only one study wich set the prevalence of NAFLD by CT images in 20%1.
Objectives: Describe the prevalence of NAFLD and fibrosis in CD and analize predictive biomarkers of NAFLD
Methods: Transversal descriptive study. 31 patients with CD; 11 active, 20 cured. Women 24 (77%), men 7 (23%). 54 years mean age. NAFLD was valorated by Hepatic Steatosis Index (HSI) and Controlled Attenuated Parameter (CAP dB/m). Fibrosis stage by FIB4 and transition elastography (kPa). Date of control of hypercortisolism was determinated by normalization of free urinary cortisol 24 hours.
Results: 31 patients. 20 (65%) cured (11 with hydrocortisone treatment) and 11 (35%) with active disease, 3 (10%) non controlled. HTA 14 (45%), dyslipemia 16 (52%), type 2 Diabetes 7 (23%). Obesity (BMI > 30 kg/m2) 15 (48%) and 10 (32%) overweight. 3 patients with previous mayor vascular event. Pathologic HSI (> 36) in 24 (77%). NAFLD clasiffication by CAP: S1 (248–268 dB/m): 3 (10%); S2 (268 –280 dB/m): 3 (10%); S3 (> 280 dB/m): 9 (29%); S0 en 16 (51%). All patients with HIS > 36 were classified as S2-3 with a correlation between HSI and CAP (coef 0,416). Besides, an association between NAFLD and active CD was observed (80% Vs 20%, P 0.07) NAFLD was also associated with obesity (83% vs 26%, P = 0,03), presence of DM, HTA and/or DLP (92% vs 53% P = 0,046) and longer time to get hormonal control (117 vs 29 months, P = 0,001). 3 (9.7%) patients with ET values >8.9 Kpa (F3-F4). All ET > 89 K Pa patients presented HSI > 36, but no one pathologic FIB4 value. ET > 8,9 kPa was associated with longer time to get hormonal control.
Conclusions: – A high prevalence of NAFLD has been observed in our series, with higer prevalence in non cured patients.
– HSI formula classified correctly NAFLD patients.
– FIB4 seems not to be a godo predictor of fibrosis.
Reference
1. A. G. Rockall et al., ‘Hepatic steatosis in Cushing’s syndrome: A radiological assessment using computed tomography,’ Eur. J. Endocrinol. 2003.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more